NASDAQ · Biotechnology

IMUX (IMUX) Stock

$14.24 -2.33% NASDAQ: IMUX Healthcare

Valuation

MetricValue
Price$14.24
Market Cap$193.97M
P/E Ratio-3.44
P/B Ratio5.49
P/S Ratio0.00
EPS (TTM)$-6.24
52-Week High$17.43
52-Week Low$5.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-157.89%
ROA-70.09%
ROCE-92.16%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.14
Current Ratio0.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-92.0M$-119.0M$-99.0M$-98.0M$-103.0M
Net Profit$-93.0M$-120.0M$-94.0M$-101.0M$-97.0M
EPS$-39.30$-37.84$-21.12$-10.03$-6.24
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$139.0M$128.0M$54.0M$41.0M$24.0M
Total Liabilities$12.0M$14.0M$25.0M$22.0M$31.0M
Cash$87.0M$107.0M$47.0M$36.0M$15.0M
Borrowings$1.0M$2.0M$1.0M$1.0M$1.0M

Latest News

Immunic to Participate in Investor Conferences in July PR Newswire · Jul 9, 2026 Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire · Jun 10, 2026 Immunic presents new vidofludimus calcium data at multiple sclerosis conference Proactive · May 28, 2026 Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PR Newswire · May 28, 2026 Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials Proactive · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-83.0M$-65.0M$-71.0M$-85.0M$-86.0M
Investing Cash Flow$0$-10.0M$9.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-41.0M$20.0M$-60.0M$-11.0M$-20.0M
Free Cash Flow$-83.0M$-65.0M$-71.0M$-85.0M$-86.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA-0.63
FCF Yield-39.20%
Quick Ratio5.05
Interest Coverage0.00
Return 1Y74.88%
Return 3Y-41.94%
Return 5Y-84.27%

Ownership

Insiders Held0.97%
Institutions Held46.90%
Institutions Float Held47.37%
Institutional HolderSharesReport Date
Marshall Wace LLP952,9662026-03-31
Aberdeen Group plc824,3942026-03-31
BVF Inc.765,2972026-03-31
Avidity Partners Management, LP669,9412026-03-31
Vanguard Capital Management LLC513,8322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACET $9.26 +0.00% -0.46 $86.56M 0.00%
ACRV $2.15 +3.86% -1.10 $92.02M 0.00%
BMEA $1.94 +7.50% -1.20 $139.90M 0.00%
CBUS $1.56 +0.00% -0.50 $119.08M 0.00%
LITS $1.04 +4.63% -0.35 $35.39M 0.00%

About IMUX

IMUX is led by CEO Daniel Vitt, employs 91 people, headquartered in US, publicly traded since 2014.

IMUX stock trades at $14.24 with a market capitalization of $193.97M. The stock is valued at a price-to-earnings (P/E) ratio of -3.44, price-to-book of 5.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.06 and $17.43, and currently trades 18.3% below its 52-week high.

On profitability, IMUX generates a return on equity (ROE) of -157.89%, return on capital employed of -92.16%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides